Fresenius Medical Care (NYSE:FMS) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note issued to investors on Tuesday. The firm set a “strong-buy” rating on the stock.

Separately, Truist Financial raised their price objective on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a research report on Monday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Fresenius Medical Care presently has an average rating of “Hold” and a consensus target price of $23.00.

Fresenius Medical Care Price Performance

Fresenius Medical Care stock opened at $20.08 on Tuesday. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45. The company has a 50-day moving average price of $19.78 and a 200 day moving average price of $20.03. Fresenius Medical Care has a 12-month low of $16.37 and a 12-month high of $22.76. The stock has a market cap of $11.78 billion, a P/E ratio of 22.54, a PEG ratio of 1.08 and a beta of 0.91.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, meeting the consensus estimate of $0.38. The firm had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. Sell-side analysts anticipate that Fresenius Medical Care will post 1.51 earnings per share for the current year.

Hedge Funds Weigh In On Fresenius Medical Care

Institutional investors have recently modified their holdings of the business. GAMMA Investing LLC boosted its holdings in Fresenius Medical Care by 21.8% in the first quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock valued at $82,000 after purchasing an additional 758 shares during the period. Uncommon Cents Investing LLC raised its holdings in shares of Fresenius Medical Care by 8.0% in the 1st quarter. Uncommon Cents Investing LLC now owns 38,810 shares of the company’s stock valued at $748,000 after purchasing an additional 2,890 shares in the last quarter. Legacy Wealth Asset Management LLC purchased a new stake in shares of Fresenius Medical Care during the 1st quarter worth $584,000. Veracity Capital LLC lifted its holdings in Fresenius Medical Care by 172.2% during the 1st quarter. Veracity Capital LLC now owns 53,023 shares of the company’s stock worth $1,022,000 after buying an additional 33,543 shares during the last quarter. Finally, ORG Partners LLC acquired a new position in shares of Fresenius Medical Care during the 1st quarter worth about $110,000. Institutional investors and hedge funds own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.